In different tumor types, underexpression of p-4EBP1 consistently acted as an indicator of better prognosis among patients with breast cancer, cholangiocarcinoma, esophageal cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, and renal cancer. Here, EIF4EBP1 is linked to breast cancer.